OPM announces poster presentation on OPM-101

OPM announces poster presentation on OPM-101, a RIPK2 kinase inhibitor, in healthy volunteers at UEG Week 2024 conference

Presentation by Professor Laurent Peyrin-Biroulet (M.D., PhD Professor of Gastroenterology at CHRU of Nancy) and Bruno Robin (PharmD, Head of OPM Clinical Development) of safety, pharmacokinetic and pharmacodynamic data from Phase 1 in healthy volunteers receiving OPM-101 in a moderated poster session

Dijon (France), October 15, 2024, at 8:00am CEST– Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announced that a scientific abstract on its leading drug candidate, OPM-101, has been presented at the United European Gastroenterology (UEG) Week congress, October 12-15, 2024, in Vienna, Austria.